Abstract
Background Cardiovascular diseases (CVDs) are the leading cause of death in most low- and middle-income countries (LMICs). CVDs and their metabolic risk factors have historically been concentrated among urban residents with higher socioeconomic status (SES) in LMICs such as India. However, as India develops, it is unclear whether these socioeconomic and geographic gradients will persist or change. Understanding these social dynamics in CVD risk is essential for mitigating the rising burden of CVDs and to reach those with the greatest needs.
Methods Using nationally representative data with biomarker measurements from the fourth (2015-16) and fifth (2019-21) Indian National Family and Health Surveys, we investigated trends in the prevalence of four CVD risk factors: tobacco consumption (self-reported, any type), unhealthy weight 
, idiabetes (random plasma glucose concentration ≥200mg/dL or self-reported diabetes), and hypertension (one of: average systolic blood pressure ≥ 140mmHg, average diastolic blood pressure ≥ 90mmHg, self-reported past diagnosis, or self-reported current antihypertensive medication use) among adults aged 15-49 years. We first described changes at the national level and then trends stratified by place of residence (urban versus rural), geographic region (northern, northeastern, central, eastern, western, southern), regional level of development (Empowered Action Group member state or not), and two measures of socioeconomic status: level of education (no education, primary incomplete, primary complete, secondary incomplete, secondary complete, higher) and wealth (quintiles).
Findings Unhealthy weight increased among all social and geographic groups but both the absolute and the relative changes were substantially higher among people with low SES (as measured by education or wealth) and in rural areas. For diabetes and hypertension, the prevalence increased for those from disadvantaged groups while staying constant or even decreasing among the wealthier and more educated. In contrast, tobacco consumption declined for all social and geographic groups.
Interpretation In 2015-16, CVD risk factors were higher among more advantaged subpopulations in India. However, between 2015-16 and 2019-21, the prevalence of these risk factors grew more rapidly for less wealthy and less educated subpopulations and those living in rural areas. These trends have resulted in CVD risk becoming far more widespread throughout the population; CVD can no longer be characterized as a wealthy urban phenomenon.
Funding This work was supported by the Alexander von Humboldt Foundation [NS]; the Stanford Diabetes Research Center [PG], and the Chan Zuckerberg Biohub [PG].
Evidence before this study We searched PubMed for work published between Jan 1, 1990, and Sep 23, 2022, with variations of the search terms “reversal hypothesis”, “social gradient”, “socioeconomic gradient”, “social difference”, “socioeconomic difference”, “socioeconomic status”, “change”, “trend”, “cardiovascular disease”, “cardiovascular risk factor”, “diabetes”, “hypertension”, “overweight”, “obesity”, “smoking”, “tobacco”, “low-income”, “lower-middle-income”, and “India” in the title or abstract. Existing studies on changes in the socioeconomic patterning of cardiovascular disease (CVD) risk factors mostly compared the size of social gradients in obesity cross-sectionally between countries at different levels of national income or development. These studies generally found higher obesity among higher socioeconomic status (SES) populations but opposite gradients for countries at higher levels of development. However, because these studies use cross-sectional comparisons, whether these patterns reflect the influence of development or other contextual factors associated with countries at different levels of development is unclear. Both for obesity and for other CVD risk factors, we found few nationally-representative studies that traced how gradients within countries changed over time as they developed. Importantly, most of these studies did not focus on India and those that did only considered single risk factors such as obesity using older data. Existing nationally representative research on India is thus predominantly cross-sectional and has only focused on the size of social gradients at single points in time. This work generally finds higher levels of unhealthy weight, diabetes, and hypertension among wealthy and educated subpopulations but lower levels of tobacco consumption. Subnational and smaller non-representative studies from India that traced changes in CVD risk factors over time provide some evidence of reversing or flattening gradients but it is unclear whether these patterns hold at regional and national levels.
Added value of this study Using data from the 2015-16 and 2019-2021 National Family and Health Surveys, we provide some of the first nationally representative evidence for trends in the prevalence of major CVD risk factors in India and how these trends have changed across social and geographic groups. Both absolute and relative increases in prevalence were far more pronounced among relatively poor and less educated populations. As a result of these trends, most CVD risk factors became more equal across population groups, or in some cases, became higher among the less compared to more educated.
Implications of all the available evidence Indians with lower SES – as measured by wealth and education – experienced considerable adverse trends in unhealthy weight, diabetes, and hypertension between 2015-16 and 2019-21. Our results reveal that CVDs can no longer be considered a problem of the affluent parts of society and suggest that CVD prevention efforts that reach less advantaged subpopulations are urgently needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Alexander von Humboldt Foundation [NS]; the Stanford Diabetes Research Center [PG] and the Chan Zuckerberg Biohub [PG]. The funders of the study had no role in study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used for the analysis is publicly accessible (https://dhsprogram.com/).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint senior authors
Other Authors:
Name: Pascal Geldsetzer, Address: Division of Primary Care and Population Health, Department of Medicine, Stanford University, 3180 Porter Drive, Palo Alto, CA 94304, USA
Name: Sneha Sarah Mani, Address: Graduate Group in Demography, University of Pennsylvania, 207, 3718 Locust Walk, Philadelphia, PA 19104, USA
Name: Aashish Gupta, Address: Harvard University, 9 Bow Street, Cambridge, MA 02138, USA
Name: Kavita Singh, Address: Heidelberg Institute of Global Health, Faculty of Medicine, Heidelberg University, Im Neuenheimer Feld 130.3, 69120 Heidelberg
Name: Mohammed K. Ali, Address: Emory University, 1516 Clifton Rd NE, R755, Atlanta, GA 30322, USA
Name: Dorairaj Prabhakaran, Address: Centre for Chronic Disease Control, C1/52, Safdarjung Development Area New Delhi 110016, India
Name: Nikhil Tandon, Address: Department of Endocrinology and Metabolism, All India Institute of Medical Sciences Ansari Nagar, New Delhi 110029, India
Name: Nikkil Sudharsanan, Address: Professorship of Behavioral Science for Disease Prevention and Health Care, Technical University of Munich Georg-Brauchle-Ring 60, Room L420, 80992 Munich, Germany
Data Availability
The data used for the analysis is publicly accessible (https://dhsprogram.com/).
